Cited 3 times in
Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2020-12-01T17:11:16Z | - |
dc.date.available | 2020-12-01T17:11:16Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180159 | - |
dc.description.abstract | Background and objectives: The effectiveness of angiotensin II receptor blockers (ARBs) compared with angiotensin converting enzyme inhibitors (ACEIs) in patients with acute myocardial infarction (AMI) has not been established. We investigated the effects of ARBs on clinical outcomes after percutaneous coronary intervention (PCI) in AMI patients. Methods: Patients receiving ACEIs or ARBs after AMI treated with PCI between January 2005 and December 2014 were selected from the Korean National Health Insurance Service database. The primary endpoint was major cardiovascular adverse event (MACE; all-cause death, myocardial infarct [MI], or stroke). Results: We included patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) (medication possession ratio ≥80%). Compared with the ACEI group, the ARB group contained more females (31% vs. 18%), were older (mean, 63 vs. 60 years), and had more comorbidities, including hypertension (62.8% vs. 44.8%), diabetes (33.9% vs. 26.4%), congestive heart failure (7.9% vs. 4.3%), chronic obstructive pulmonary disease (25.5% vs. 18.9%), and end-stage renal disease (1.3% vs. 0.4%) (p<0.001 for all). After propensity score-matching, ARBs were associated with a 23% lower risk of MACE (hazard ratio [HR], 0.774; 95% confidence interval [CI], 0.715-0.838; p<0.001) than ACEIs. ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659-0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638-0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773-0.861; p<0.001). Conclusions: ARB use was associated with a lower risk of MACE, MI, and revascularization than ACEIs in our retrospective analysis of AMI patients who underwent PCI. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Korean Society of Circulation | - |
dc.relation.isPartOf | KOREAN CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Gwang Sil Kim | - |
dc.contributor.googleauthor | Young Guk Ko | - |
dc.contributor.googleauthor | Yongsung Suh | - |
dc.contributor.googleauthor | Hoyoun Won | - |
dc.contributor.googleauthor | Sung Jin Hong | - |
dc.contributor.googleauthor | Chul Min Ahn | - |
dc.contributor.googleauthor | Jung Sun Kim | - |
dc.contributor.googleauthor | Byeong Keuk Kim | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.4070/kcj.2020.0057 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J01952 | - |
dc.identifier.eissn | 1738-5555 | - |
dc.identifier.pmid | 32725998 | - |
dc.subject.keyword | Angiotensin converting enzyme inhibitors | - |
dc.subject.keyword | Angiotensin type II receptor blockers | - |
dc.subject.keyword | Drug therapy | - |
dc.subject.keyword | Myocardial infarction | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 50 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 984 | - |
dc.citation.endPage | 994 | - |
dc.identifier.bibliographicCitation | KOREAN CIRCULATION JOURNAL, Vol.50(11) : 984-994, 2020-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.